Download PDF

Other users also viewed these articles

Epidemiological characteristics and adverse events of patients with psoriatic arthritis undergoing treatment with biological therapies in Galicia Carlos García Porrúa; Francisco José Maceiras Pan; José Antonio Mosquera Martínez; Loreto Carmona; Blanca Correa Rey; Luis Fernández Domínguez; María Noelia Álvarez Rivas; José Antonio Pinto Tasende;
Reumatol Clin. 2021;17:150-4
Secukinumab as biological treatment for psoriatic arthritis in real clinical practice José A. Pinto Tasende; Francisco J. Maceiras Pan; José A. Mosquera Martínez; Luis Fernández Dominguez; Blanca Correa Rey; Carlos García Porrúa;
Reumatol Clin. 2021;17:203-6
One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry Clementina López-Medina; Lucía Otero-Varela; Fernando Sánchez-Alonso; Vega Jovaní; Lorena Expósito-Pérez; Sheila Melchor-Díaz; Yanira Pérez-Vera; Paula Pretel-Ruiz; Javier Manero; Antonio Mera-Varela; Lourdes Mateo; Dolores Ruiz-Montesino; José Andrés Lorenzo-Martín; Teresa Pedraz-Penalva; Isabel Castrejón;
Reumatol Clin. 2025;21: